Sun's Taro recalls 62,800 tubes of Topicort

Sun Pharma Managing Director Dilip Shanghvi

Sun Pharmaceutical’s U.S.-based Taro Pharmaceutical Industries helped the Indian drugmaker boost its U.S. sales in its last fiscal year, but the skin care specialist has hit a small manufacturing glitch and is recalling a product that failed to hit some specifications.

According to the most recent FDA Enforcement Report, Taro is voluntarily recalling 62,800 tubes of Topicort Cream (desoximetasone) manufactured in Canada because the product may be subpotent. The steroid cream is used to treat skin irritations.

The recall comes as the Indian drugmaker has its hands full with manufacturing problems in India where it is working to get some of the Ranbaxy plants it acquired last year ready for reinspections; it's also doing remediation at a legacy plant that is key to U.S. sales. The Ranbaxy plants had been banned by the FDA for a number of manufacturing problems ahead of Sun’s $4 billion buyout of Ranbaxy.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

In an analyst call this week for its fiscal year ended March 31, Sun Managing Director Dilip Shanghvi said the company hopes that one of the Ranbaxy plants will be reinspected by the FDA by the middle of FY17.

But Sun is also having to do remediation at its plant in Halol. That interruption has dampened its U.S. sales over the last year. Citing an analyst report from Jefferies, NDTV reports upgrades at Halol are expected to be completed by the end of June, which will mean Sun will have several more quarters of dampened sales before it can get back on track.  

As for Taro, it posted Q4 sales of $265 million, up 9%, and full-year sales of $951 million, up 10%. That helped the Indian drugmaker grow Q4 U.S. sales to $580 million, up 19%, and accounting for 52% of the company’s total sales there. But for the full year, Sun's U.S. sales of $2 billion were off 8%.

- find the recall here 
- get Sun’s financial release 
- read the LiveMint story

Related Articles: 
Sun looks for FDA reinspection of Ranbaxy plant this year 
Sun sales, earnings pummeled by plant problems, integration costs 
Sun Pharma hopes to turn fortunes of Ranbaxy around with $3.2B buyout 
Sun recalls 1M-plus boxes of generic Claritin made at Ohm Labs

Suggested Articles

Neopharma, which has been buying and building plants for several years, is buying a sterile injectables plant and assets in Japan from India’s Lupin. 

Already knocked by the FDA four times this year, Dr. Reddy’s now has a fifth Form 483 to dwell on. This time it’s at a plant with a history of faults.

In a warning letter, the FDA details how a Chinese OTC drugmaker handed over documents faked just for the agency's inspection—and admitted it.